102 results
Page 3 of 6
8-K
EX-99.1
r392vj 64
14 Sep 21
Other Events
4:29pm
8-K
EX-99.1
gs7nu1ozrkf24o
14 Sep 21
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
7:00am
8-K
EX-99.1
ei0ip34
4 Aug 21
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
7:05am
8-K
EX-99.1
u7zn2 v4zxqaglmfvnzl
1 Jul 21
Highlights the broader potential of Orchard’s ex vivo HSC gene therapy platform approach in new and larger indications
5:02pm
8-K
EX-99.1
1zim o6v9lb
29 Jun 21
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
7:05am
8-K
EX-99.1
z8ybv tgwz5abqx
13 May 21
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
7:05am
8-K
EX-99.1
gci1xton ap
11 May 21
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID
6:05am
8-K
EX-99.1
a146 o3yjq8ookqyni
2 Mar 21
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
7:05am
8-K
EX-99.2
5nqigr7
9 Feb 21
Orchard Therapeutics Announces $150 Million Strategic Financing
7:10am
8-K
EX-99.1
3fxl2oqogje9z
9 Feb 21
Orchard Therapeutics Announces $150 Million Strategic Financing
7:10am
8-K
EX-99.1
8725 sdwrebe7
29 Jan 21
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
7:03am
8-K
EX-99.1
y9shw3yjwxlu7
19 Jan 21
Orchard Therapeutics Secures Partnerships to Broaden Access to LibmeldyTM for Eligible Patients in Middle East & Turkey
7:03am
8-K
EX-99.1
ms4piv xr1r1gfcoqw
14 Jan 21
Interactions with FDA anticipated by mid-2021 to determine the BLA filing strategy for OTL-200
7:03am
8-K
EX-99.1
k0baot4bson1e
11 Jan 21
Results of Operations and Financial Condition
7:05am